These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 8369109

  • 1. Vitamin E attenuates the development of haloperidol-induced dopaminergic hypersensitivity in rats: possible implications for tardive dyskinesia.
    Gattaz WF, Emrich A, Behrens S.
    J Neural Transm Gen Sect; 1993; 92(2-3):197-201. PubMed ID: 8369109
    [Abstract] [Full Text] [Related]

  • 2. MK-771 antagonizes the enhanced response to apomorphine in rats treated chronically with haloperidol - implications for tardive dyskinesia.
    Yarbrough GG, Faison EP, Antolik EK.
    Neurosci Lett; 1982 Dec 31; 34(3):321-3. PubMed ID: 6819493
    [Abstract] [Full Text] [Related]

  • 3. Protective effect of Curcumin, the active principle of turmeric (Curcuma longa) in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes in rat brain.
    Bishnoi M, Chopra K, Kulkarni SK.
    Pharmacol Biochem Behav; 2008 Feb 31; 88(4):511-22. PubMed ID: 18022680
    [Abstract] [Full Text] [Related]

  • 4. Behavioural and biochemical alterations following haloperidol treatment and withdrawal: the animal model of tardive dyskinesia reexamined.
    Rastogi SK, Rastogi RB, Singhal RL, Lapierre YD.
    Prog Neuropsychopharmacol Biol Psychiatry; 1983 Feb 31; 7(2-3):153-64. PubMed ID: 6137027
    [Abstract] [Full Text] [Related]

  • 5. The pathophysiology of tardive dyskinesia.
    Klawans HL, Carvey P, Tanner CM, Goetz CG.
    J Clin Psychiatry; 1985 Apr 31; 46(4 Pt 2):38-41. PubMed ID: 2858479
    [Abstract] [Full Text] [Related]

  • 6. Molindone compared to haloperidol in a guinea-pig model of tardive dyskinesia.
    Koller W, Curtin J, Fields J.
    Neuropharmacology; 1984 Oct 31; 23(10):1191-4. PubMed ID: 6240609
    [Abstract] [Full Text] [Related]

  • 7. Antagonism of dopamine supersensitivity by estrogen: neurochemical studies in an animal model of tardive dyskinesia.
    Gordon JH, Diamond BI.
    Biol Psychiatry; 1981 Apr 31; 16(4):365-71. PubMed ID: 7194695
    [Abstract] [Full Text] [Related]

  • 8. Estrogen in experimental tardive dyskinesia.
    Gordon JH, Borison RL, Diamond BI.
    Neurology; 1980 May 31; 30(5):551-4. PubMed ID: 7189262
    [Abstract] [Full Text] [Related]

  • 9. Amantadine reduces haloperidol-induced dopamine receptor hypersensitivity in the striatum.
    Allen RM, Lane JD, Brauchi JT.
    Eur J Pharmacol; 1980 Jul 25; 65(2-3):313-5. PubMed ID: 7190503
    [Abstract] [Full Text] [Related]

  • 10. The effect of thioridazine on haloperidol induced behavioral hypersensitivity.
    Klawans HL, Carvey PM, Nelson D, Tanner CM, Goetz CG.
    Life Sci; 1986 May 12; 38(19):1707-14. PubMed ID: 3702600
    [Abstract] [Full Text] [Related]

  • 11. Effect of D1 and D2 agonists in primates withdrawn from long-term treatment with haloperidol: the potential role of dopamine D1 receptors in dyskinesia.
    Lublin H, Gerlach J, Peacock L.
    Clin Neuropharmacol; 1992 Dec 12; 15(6):448-58. PubMed ID: 1362136
    [Abstract] [Full Text] [Related]

  • 12. Further dopaminergic supersensitivity to dopamine agonists by subchronic administration of haloperidol in rats treated with colchicine.
    Kamata K, Okuyama S, Hashimoto S, Aihara H, Kasuya Y.
    Jpn J Pharmacol; 1986 Oct 12; 42(2):329-32. PubMed ID: 3795627
    [Abstract] [Full Text] [Related]

  • 13. Effect of daily dose of chronic haloperidol and chronic apomorphine on behavioral hypersensitivity in the rat.
    Kinon BJ, Merson D, Kane JM.
    Psychopharmacology (Berl); 1984 Oct 12; 84(3):347-51. PubMed ID: 6440181
    [Abstract] [Full Text] [Related]

  • 14. Behavioural subsensitivity induced by long-term administration of a low dose of haloperidol to rats.
    Frussa-Filho R, Abílio VC, Bergamo M, Palermo-Neto J.
    J Pharm Pharmacol; 1997 Apr 12; 49(4):412-5. PubMed ID: 9232539
    [Abstract] [Full Text] [Related]

  • 15. Theophylline, adenosine receptor antagonist prevents behavioral, biochemical and neurochemical changes associated with an animal model of tardive dyskinesia.
    Bishnoi M, Chopra K, Kulkarni SK.
    Pharmacol Rep; 2007 Apr 12; 59(2):181-91. PubMed ID: 17556796
    [Abstract] [Full Text] [Related]

  • 16. Effects of buspirone on dopaminergic supersensitivity.
    Queiroz CM, Frussa-Filho R.
    Life Sci; 1997 Apr 12; 61(4):371-82. PubMed ID: 9244363
    [Abstract] [Full Text] [Related]

  • 17. The effect of lithium on an animal model of tardive dyskinesia.
    Klawans HL, Weiner WJ, Nausieda PA.
    Prog Neuropsychopharmacol; 1977 Apr 12; 1(1-2):53-60. PubMed ID: 569341
    [No Abstract] [Full Text] [Related]

  • 18. MSH and MIF-I in animal models of tardive dyskinesia.
    Davis KL, Kastin AJ, Beilstein BA, Vento AL.
    Pharmacol Biochem Behav; 1980 Jul 12; 13(1):37-40. PubMed ID: 6105677
    [Abstract] [Full Text] [Related]

  • 19. Possible antioxidant and neuroprotective mechanisms of FK506 in attenuating haloperidol-induced orofacial dyskinesia.
    Singh A, Naidu PS, Kulkarni SK.
    Eur J Pharmacol; 2003 Sep 12; 477(2):87-94. PubMed ID: 14519411
    [Abstract] [Full Text] [Related]

  • 20. Dopaminergic supersensitivity: influence of dopamine agonists, cholinergics, anticholinergics, and drugs used for the treatment of tardive dyskinesia.
    Christensen AV, Nielsen IM.
    Psychopharmacology (Berl); 1979 Apr 11; 62(2):111-6. PubMed ID: 111273
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.